alfuzosin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antihypertensive substances, prazosin derivatives 115 81403-80-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • alfuzosin
  • alfuzosin hydrochloride
  • xatral
  • SL 77
  • alfuzosin HCl
Alfuzosin is a selective antagonist of post-synaptic alpha1-adrenoreceptors, which are located in the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra.
  • Molecular weight: 389.46
  • Formula: C19H27N5O4
  • CLOGP: 2.35
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 2
  • TPSA: 111.83
  • ALOGS: -3.14
  • ROTB: 8
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
7.50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 11 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.34 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 55 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.50 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 5.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.14 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 4.80 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,BRAF,EIF2AK3,GRK2,MAP3K21,MAPK7,PDK1,PDK2,PDK4,PRKDC 10
kinase-selectivity-class PRKDC,TTK 2
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
June 12, 2003 FDA COVIS PHARMA SARL

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Apraxia 66.63 42.10 13 1135 2249 90625050
Disorientation 59.57 42.10 22 1126 44092 90583207
Dementia 56.00 42.10 18 1130 23843 90603456
Perseveration 53.66 42.10 8 1140 277 90627022
Drug interaction 44.91 42.10 33 1115 276420 90350879
Hallucination, visual 44.45 42.10 15 1133 23077 90604222
Hyperreflexia 42.72 42.10 11 1137 6646 90620653

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug dispensed to wrong patient 183.40 12.98 45 23301 472 42597517
Acute kidney injury 152.77 12.98 494 22852 366843 42231146
Orthostatic hypotension 123.54 12.98 115 23231 30455 42567534
Syncope 117.74 12.98 202 23144 99204 42498785
Antimicrobial susceptibility test resistant 113.21 12.98 29 23317 367 42597622
Minimum inhibitory concentration 103.29 12.98 23 23323 151 42597838
Cholestasis 98.29 12.98 105 23241 32774 42565215
Therapeutic response delayed 91.80 12.98 28 23318 691 42597298
Drug interaction 91.35 12.98 337 23009 266662 42331327
Wrong patient received product 88.66 12.98 42 23304 3541 42594448
Hypotension 87.13 12.98 324 23022 257307 42340682
Fall 86.13 12.98 303 23043 234217 42363772
Agranulocytosis 76.44 12.98 89 23257 30523 42567466
Confusional state 70.70 12.98 227 23119 167370 42430619
Coma 66.19 12.98 111 23235 53443 42544546
Hepatocellular injury 62.75 12.98 71 23275 23607 42574382
Wrong product administered 61.92 12.98 40 23306 6186 42591803
Thrombocytopenia 53.46 12.98 226 23120 190053 42407936
Urinary retention 51.49 12.98 87 23259 42127 42555862
Product administration error 48.59 12.98 55 23291 18288 42579701
Product dispensing error 47.85 12.98 37 23309 7602 42590387
Toxicity to various agents 45.99 12.98 35 23311 229101 42368888
Product storage error 45.15 12.98 42 23304 11098 42586891
Hepatic cytolysis 44.89 12.98 64 23282 26780 42571209
Expired product administered 44.52 12.98 28 23318 4135 42593854
Eosinophilia 41.72 12.98 69 23277 32830 42565159
Hepatitis cholestatic 39.74 12.98 37 23309 9787 42588202
Purpura 39.17 12.98 40 23306 11839 42586150
Growth hormone deficiency 38.60 12.98 12 23334 316 42597673
Pemphigoid 38.52 12.98 39 23307 11428 42586561
Staring 37.47 12.98 18 23328 1565 42596424
Allergy to animal 36.25 12.98 13 23333 537 42597452
Disorganised speech 36.13 12.98 17 23329 1411 42596578
Lactic acidosis 35.11 12.98 77 23269 45184 42552805
Vertigo 34.45 12.98 65 23281 34282 42563707
Lichenoid keratosis 33.54 12.98 23 23323 3927 42594062
Cell death 31.88 12.98 20 23326 2939 42595050
Completed suicide 31.74 12.98 7 23339 96458 42501531
Melaena 31.29 12.98 67 23279 38679 42559310
Drug ineffective 31.22 12.98 210 23136 629987 41968002
Toxic skin eruption 31.10 12.98 38 23308 13692 42584297
Bradycardia 30.86 12.98 110 23236 85374 42512615
Brain stem haematoma 29.43 12.98 8 23338 129 42597860
Pancreatitis acute 29.39 12.98 60 23286 33504 42564485
Cardiovascular insufficiency 29.36 12.98 16 23330 1810 42596179
Retrograde ejaculation 29.17 12.98 11 23335 524 42597465
Pituitary tumour benign 28.70 12.98 13 23333 989 42597000
Nasal discomfort 28.64 12.98 15 23331 1567 42596422
Neutropenia 28.57 12.98 197 23149 199234 42398755
Hallucination, visual 27.88 12.98 45 23301 20975 42577014
Hepatitis 26.55 12.98 51 23295 27249 42570740
Faecal vomiting 26.43 12.98 11 23335 681 42597308
Daydreaming 25.96 12.98 11 23335 712 42597277
Hyponatraemia 25.75 12.98 117 23229 101345 42496644
Parkinsonism 25.03 12.98 30 23316 10593 42587396
Campylobacter gastroenteritis 24.66 12.98 12 23334 1073 42596916
Hyperlipasaemia 24.53 12.98 10 23336 587 42597402
Altered state of consciousness 24.09 12.98 51 23295 29208 42568781
Petit mal epilepsy 23.56 12.98 18 23328 3632 42594357
Blood thyroid stimulating hormone decreased 23.28 12.98 15 23331 2308 42595681
Post procedural haemorrhage 23.11 12.98 27 23319 9285 42588704
Hypovolaemic shock 22.99 12.98 26 23320 8633 42589356
Campylobacter test positive 22.93 12.98 6 23340 83 42597906
Hyperkalaemia 22.87 12.98 96 23250 80362 42517627
Hallucination 22.48 12.98 76 23270 57431 42540558
Anaemia 22.28 12.98 243 23103 280035 42317954
Subileus 21.93 12.98 17 23329 3504 42594485
Dermatitis exfoliative generalised 21.77 12.98 21 23325 5803 42592186
Normocytic anaemia 21.70 12.98 17 23329 3560 42594429
Dysuria 20.90 12.98 50 23296 31046 42566943
Disease progression 20.79 12.98 29 23317 143627 42454362
Capillary fragility 20.68 12.98 5 23341 49 42597940
Contraindicated product prescribed 19.80 12.98 9 23337 690 42597299
Treatment failure 19.69 12.98 5 23341 62619 42535370
Generalised onset non-motor seizure 19.61 12.98 4 23342 16 42597973
Soft tissue mass 19.48 12.98 10 23336 1002 42596987
Atrioventricular block second degree 19.35 12.98 17 23329 4170 42593819
Illusion 19.33 12.98 10 23336 1019 42596970
Incontinence 18.98 12.98 21 23325 6809 42591180
Pelvic fracture 18.95 12.98 14 23332 2687 42595302
Myalgia 18.85 12.98 103 23243 95977 42502012
Dizziness 18.84 12.98 214 23132 249040 42348949
Hypokalaemia 18.41 12.98 83 23263 71638 42526351
Hanging 18.40 12.98 6 23340 185 42597804
Steroid diabetes 18.27 12.98 14 23332 2838 42595151
Haemoglobinaemia 18.25 12.98 6 23340 190 42597799
Febrile bone marrow aplasia 18.09 12.98 25 23321 10156 42587833
Stool analysis abnormal 17.68 12.98 5 23341 94 42597895
Loss of consciousness 17.44 12.98 98 23248 92256 42505733
Angina pectoris 17.07 12.98 48 23298 32848 42565141
Off label use 16.69 12.98 248 23098 638087 41959902
Tonic clonic movements 16.67 12.98 10 23336 1357 42596632
On and off phenomenon 15.87 12.98 14 23332 3453 42594536
Muscle haemorrhage 15.66 12.98 15 23331 4110 42593879
Death 15.64 12.98 174 23172 471011 42126978
Erectile dysfunction 15.61 12.98 39 23307 24874 42573115
Cutaneous vasculitis 15.56 12.98 19 23327 6841 42591148
Prostatomegaly 15.47 12.98 18 23328 6159 42591830
Hypernatraemia 15.43 12.98 23 23323 10009 42587980
Pyelitis 15.37 12.98 5 23341 153 42597836
Diffuse large B-cell lymphoma recurrent 15.29 12.98 16 23330 4870 42593119
Dyspnoea at rest 15.28 12.98 15 23331 4234 42593755
Ischaemic stroke 15.21 12.98 36 23310 22197 42575792
Drug intolerance 15.21 12.98 13 23333 80411 42517578
Pulmonary interstitial emphysema syndrome 15.17 12.98 7 23339 556 42597433
Behaviour disorder 15.13 12.98 19 23327 7035 42590954
Haematuria 14.91 12.98 67 23279 57732 42540257
Vitamin B12 decreased 14.90 12.98 10 23336 1648 42596341
Cystitis interstitial 14.87 12.98 5 23341 170 42597819
Subcapsular splenic haematoma 14.86 12.98 4 23342 62 42597927
Tendon rupture 14.59 12.98 20 23326 8063 42589926
Disorientation 14.14 12.98 48 23298 36341 42561648
Ketonuria 14.07 12.98 7 23339 657 42597332
Cardiac failure congestive 13.71 12.98 16 23330 85586 42512403
Dehydration 13.68 12.98 128 23218 141639 42456350
Prostatitis 13.68 12.98 17 23329 6231 42591758
Acute generalised exanthematous pustulosis 13.64 12.98 20 23326 8575 42589414
Neutrophil count decreased 13.60 12.98 9 23337 63406 42534583
Paramnesia 13.56 12.98 3 23343 19 42597970
Amaurosis fugax 13.38 12.98 7 23339 730 42597259
Rash maculo-papular 13.30 12.98 48 23298 37455 42560534
Blood pressure decreased 13.14 12.98 65 23281 58267 42539722
Bacterial prostatitis 13.03 12.98 4 23342 101 42597888
Amyotrophy 12.98 12.98 6 23340 478 42597511

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 311.89 14.32 488 20849 634942 109933020
Drug interaction 205.48 14.32 355 20982 499828 110068134
Hypotension 139.53 14.32 310 21027 523539 110044423
Cholestasis 138.00 14.32 108 21229 64410 110503552
Antimicrobial susceptibility test resistant 134.85 14.32 28 21309 406 110567556
Syncope 131.42 14.32 178 21159 202358 110365604
Orthostatic hypotension 131.22 14.32 106 21231 66143 110501819
Drug dispensed to wrong patient 130.23 14.32 30 21307 719 110567243
Minimum inhibitory concentration 127.36 14.32 23 21314 150 110567812
Agranulocytosis 118.48 14.32 97 21240 61663 110506299
Coma 104.23 14.32 121 21216 117748 110450214
Thrombocytopenia 100.18 14.32 213 21124 348672 110219290
Therapeutic response delayed 97.81 14.32 27 21310 1363 110566599
Fall 95.50 14.32 294 21043 603188 109964774
Wrong patient received product 91.94 14.32 38 21299 6636 110561326
Wrong product administered 82.70 14.32 41 21296 10919 110557043
Hepatocellular injury 79.67 14.32 71 21266 50571 110517391
Neutropenia 79.31 14.32 203 21134 374417 110193545
Confusional state 76.54 14.32 231 21106 468449 110099513
Urinary retention 74.44 14.32 79 21258 69604 110498358
Hallucination, visual 69.30 14.32 59 21278 39546 110528416
Hepatic cytolysis 65.26 14.32 66 21271 54987 110512975
Eosinophilia 64.23 14.32 67 21270 57869 110510093
Bradycardia 60.47 14.32 108 21229 155409 110412553
Hyperkalaemia 57.60 14.32 98 21239 135698 110432264
Hepatitis cholestatic 57.26 14.32 38 21299 17528 110550434
Product administration error 56.21 14.32 51 21286 37166 110530796
Pemphigoid 55.62 14.32 39 21298 19668 110548294
Product dispensing error 54.84 14.32 36 21301 16309 110551653
Lactic acidosis 54.77 14.32 78 21259 92733 110475229
Expired product administered 53.67 14.32 28 21309 8292 110559670
Hyponatraemia 51.33 14.32 123 21214 217530 110350432
Disorientation 50.21 14.32 65 21272 70606 110497356
Pancreatitis acute 50.13 14.32 60 21277 60214 110507748
Alopecia 49.70 14.32 6 21331 364747 110203215
Purpura 48.21 14.32 39 21298 24349 110543613
Drug intolerance 47.95 14.32 10 21327 406502 110161460
Melaena 46.92 14.32 62 21275 68695 110499267
Growth hormone deficiency 46.54 14.32 12 21325 465 110567497
Lichenoid keratosis 45.85 14.32 23 21314 6279 110561683
Pain 45.85 14.32 71 21266 954884 109613078
Staring 45.09 14.32 18 21319 2874 110565088
Toxic skin eruption 44.11 14.32 39 21298 27476 110540486
Haematuria 43.54 14.32 66 21271 82939 110485023
Treatment failure 41.91 14.32 3 21334 277231 110290731
Altered state of consciousness 40.93 14.32 53 21284 57573 110510389
Swelling 40.65 14.32 9 21328 351032 110216930
Infusion related reaction 39.88 14.32 12 21325 381150 110186812
Disorganised speech 39.47 14.32 17 21320 3286 110564676
Ischaemic stroke 39.21 14.32 44 21293 41219 110526743
Cell death 38.82 14.32 20 21317 5771 110562191
Retrograde ejaculation 38.45 14.32 10 21327 401 110567561
Dehydration 38.45 14.32 130 21207 279381 110288581
Headache 38.27 14.32 70 21267 882307 109685655
Product storage error 37.25 14.32 32 21305 21696 110546266
Renal failure 37.20 14.32 112 21225 226462 110341500
Anaemia 36.86 14.32 205 21132 546881 110021081
Abdominal discomfort 36.74 14.32 15 21322 393843 110174119
Joint swelling 36.50 14.32 20 21317 442825 110125137
Hypovolaemic shock 34.64 14.32 26 21311 14557 110553405
Rheumatoid arthritis 34.04 14.32 8 21329 299605 110268357
Hallucination 33.85 14.32 66 21271 101366 110466596
Allergy to animal 33.66 14.32 13 21324 1903 110566059
Cardiovascular insufficiency 33.09 14.32 15 21322 3273 110564689
Parkinsonism 32.71 14.32 30 21307 22157 110545805
Vertigo 32.05 14.32 59 21278 86811 110481151
Arthropathy 32.04 14.32 8 21329 287514 110280448
Daydreaming 31.69 14.32 11 21326 1191 110566771
Brain stem haematoma 30.83 14.32 7 21330 157 110567805
Hepatic enzyme increased 30.28 14.32 12 21325 320880 110247082
Campylobacter gastroenteritis 30.06 14.32 12 21325 1917 110566045
Dermatitis exfoliative generalised 29.31 14.32 21 21316 10951 110557011
Faecal vomiting 28.85 14.32 11 21326 1555 110566407
Petit mal epilepsy 28.73 14.32 18 21319 7529 110560433
Perseveration 28.69 14.32 8 21329 419 110567543
Pituitary tumour benign 28.69 14.32 13 21324 2834 110565128
Completed suicide 28.48 14.32 6 21331 242375 110325587
Pemphigus 28.08 14.32 4 21333 214566 110353396
Weight increased 27.86 14.32 24 21313 419620 110148342
Pneumonia aspiration 27.28 14.32 53 21284 81180 110486782
Erectile dysfunction 27.18 14.32 25 21312 18531 110549431
Behaviour disorder 27.01 14.32 19 21318 9628 110558334
Hypersensitivity 26.95 14.32 23 21314 403975 110163987
Rash maculo-papular 26.87 14.32 50 21287 74172 110493790
Nasopharyngitis 26.86 14.32 22 21315 394339 110173623
Prostatomegaly 26.57 14.32 14 21323 4228 110563734
Febrile bone marrow aplasia 26.50 14.32 24 21313 17441 110550521
Campylobacter test positive 26.32 14.32 6 21331 137 110567825
Apraxia 25.99 14.32 13 21324 3527 110564435
Loss of consciousness 25.84 14.32 90 21247 196216 110371746
Hyperlipasaemia 25.79 14.32 10 21327 1479 110566483
Drug hypersensitivity 25.54 14.32 30 21307 454060 110113902
Soft tissue mass 25.51 14.32 10 21327 1523 110566439
Muscle haemorrhage 25.19 14.32 16 21321 6853 110561109
Tonic clonic movements 25.15 14.32 12 21325 2940 110565022
Sinusitis 25.02 14.32 13 21324 296675 110271287
Atrioventricular block second degree 24.99 14.32 17 21320 8164 110559798
Prostatitis 24.95 14.32 14 21323 4787 110563175
Cardiac failure 24.67 14.32 86 21251 187540 110380422
Synovitis 24.65 14.32 11 21326 274081 110293881
Hepatitis 24.64 14.32 54 21283 90000 110477962
Pericarditis 24.59 14.32 6 21331 219108 110348854
Inappropriate antidiuretic hormone secretion 23.83 14.32 31 21306 33820 110534142
Cerebral haemorrhage 23.81 14.32 44 21293 64924 110503038
Steroid diabetes 23.77 14.32 14 21323 5240 110562722
Cardio-respiratory arrest 23.65 14.32 62 21275 115774 110452188
Subileus 23.62 14.32 15 21322 6422 110561540
Peripheral swelling 23.47 14.32 26 21311 404008 110163954
Hypokalaemia 23.45 14.32 83 21254 182365 110385597
Bicytopenia 23.02 14.32 15 21322 6709 110561253
Blood cholesterol increased 22.93 14.32 4 21333 184781 110383181
Illusion 22.90 14.32 10 21327 1997 110565965
Stomatitis 22.55 14.32 12 21325 270230 110297732
Status epilepticus 22.36 14.32 29 21308 31542 110536420
Cutaneous vasculitis 22.34 14.32 19 21318 12710 110555252
Dysuria 22.33 14.32 41 21296 60190 110507772
Pulmonary interstitial emphysema syndrome 22.13 14.32 7 21330 568 110567394
Blood thyroid stimulating hormone decreased 22.01 14.32 15 21322 7224 110560738
Discomfort 22.01 14.32 7 21330 214700 110353262
Drug ineffective 21.98 14.32 188 21149 1520352 109047610
Gout 21.96 14.32 31 21306 36535 110531427
Wound 21.73 14.32 9 21328 234428 110333534
Nasal discomfort 21.68 14.32 14 21323 6167 110561795
Therapeutic product effect decreased 21.67 14.32 10 21327 244306 110323656
Normocytic anaemia 21.10 14.32 14 21323 6453 110561509
Haemoglobinaemia 20.73 14.32 6 21331 360 110567602
Tendon rupture 20.68 14.32 19 21318 14059 110553903
On and off phenomenon 20.58 14.32 12 21325 4412 110563550
Acute generalised exanthematous pustulosis 20.41 14.32 23 21314 21641 110546321
Ill-defined disorder 20.35 14.32 3 21334 156850 110411112
Therapeutic product effect incomplete 20.10 14.32 9 21328 223796 110344166
Dyspnoea at rest 20.09 14.32 15 21322 8331 110559631
Blood pressure decreased 19.92 14.32 58 21279 115033 110452929
Incontinence 19.81 14.32 20 21317 16615 110551347
Pyelitis 19.80 14.32 6 21331 422 110567540
Myalgia 19.63 14.32 90 21247 222291 110345671
Product use issue 19.29 14.32 19 21318 311676 110256286
Subdural haematoma 19.13 14.32 29 21308 36425 110531537
Disturbance in attention 19.07 14.32 39 21298 61956 110506006
Hanging 19.00 14.32 5 21332 210 110567752
Wheezing 18.96 14.32 13 21324 255217 110312745
Migraine 18.68 14.32 5 21332 171647 110396315
Musculoskeletal stiffness 18.56 14.32 16 21321 279806 110288156
Inferior vena cava dilatation 18.56 14.32 7 21330 960 110567002
Contraindicated product prescribed 18.56 14.32 9 21328 2284 110565678
Prostate cancer 18.43 14.32 29 21308 37612 110530350
Myoclonus 18.39 14.32 27 21310 32971 110534991
International normalised ratio increased 18.28 14.32 47 21290 86725 110481237
Cerebral haematoma 18.19 14.32 15 21322 9617 110558345
Atrial fibrillation 18.14 14.32 90 21247 229552 110338410
Folliculitis 18.03 14.32 5 21332 167648 110400314
Capillary fragility 17.87 14.32 5 21332 265 110567697
Agitation 17.71 14.32 55 21282 112996 110454966
Generalised onset non-motor seizure 17.65 14.32 4 21333 89 110567873
Bacterial prostatitis 17.56 14.32 4 21333 91 110567871
Acquired haemophilia 17.39 14.32 9 21328 2622 110565340
Lymphopenia 17.03 14.32 29 21308 40141 110527821
Osteoarthritis 16.94 14.32 7 21330 182616 110385346
Amyotrophy 16.92 14.32 6 21331 692 110567270
Miosis 16.84 14.32 21 21316 21962 110546000
Nausea 16.84 14.32 155 21182 1235535 109332427
Pallor 16.76 14.32 35 21302 56432 110511530
Hyperkeratosis 16.64 14.32 14 21323 9225 110558737
Benign prostatic hyperplasia 16.57 14.32 19 21318 18215 110549747
Psychomotor hyperactivity 16.55 14.32 20 21317 20257 110547705
Arthralgia 16.44 14.32 86 21251 779546 109788416
Blister 16.34 14.32 12 21325 227364 110340598
Acute coronary syndrome 16.01 14.32 21 21316 23091 110544871
Intraventricular haemorrhage 15.78 14.32 11 21326 5496 110562466
Bursitis 15.71 14.32 3 21334 129915 110438047
Jaundice 15.61 14.32 35 21302 59201 110508761
Paramnesia 15.21 14.32 3 21334 33 110567929
Oversensing 14.82 14.32 3 21334 38 110567924
Dihydrotestosterone increased 14.54 14.32 3 21334 42 110567920
Toxicity to various agents 14.53 14.32 46 21291 480509 110087453
Pancytopenia 14.37 14.32 79 21258 209534 110358428
Atrioventricular block 14.36 14.32 17 21320 16860 110551102

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G04CA01 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
Alpha-adrenoreceptor antagonists
ATC G04CA51 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
Alpha-adrenoreceptor antagonists
FDA MoA N0000000099 Adrenergic alpha-Antagonists
FDA EPC N0000175553 alpha-Adrenergic Blocker
MeSH PA D000317 Adrenergic alpha-Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018663 Adrenergic Agents
MeSH PA D018674 Adrenergic Antagonists
MeSH PA D058668 Adrenergic alpha-1 Receptor Antagonists
MeSH PA D064804 Urological Agents
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:35705 immunosuppressive agent
CHEBI has role CHEBI:37890 ฮฑ-adrenergic antagonist
CHEBI has role CHEBI:50503 laxative

Related Drugs by ATC class:

G04CA Alpha-adrenoreceptor antagonists 8 drugs
doxazosindutasteridefinasteridesilodosinsolifenacintadalafiltamsulosinterazosin

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Benign prostatic hyperplasia indication 266569009
Orthostatic hypotension contraindication 28651003
Torsades de pointes contraindication 31722008
Low blood pressure contraindication 45007003
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Cataract surgery contraindication 110473004
Prolonged QT interval contraindication 111975006
Angina pectoris contraindication 194828000
Micturition syncope contraindication 234168001
Disease of liver contraindication 235856003 DOID:409
Intraoperative floppy iris syndrome contraindication 418801006
Congenital long QT syndrome contraindication 442917000
Progressive Angina Pectoris contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.09 acidic
pKa2 7.22 Basic
pKa3 0.97 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Alpha-1A adrenergic receptor GPCR ANTAGONIST Ki 8.09 CHEMBL CHEMBL
Alpha-1D adrenergic receptor GPCR ANTAGONIST Ki 8.44 CHEMBL CHEMBL
Alpha-1B adrenergic receptor GPCR ANTAGONIST Ki 8.55 CHEMBL CHEMBL
Acetylcholinesterase Enzyme IC50 7.75 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.83 CHEMBL
Alpha-1D adrenergic receptor GPCR Ki 8.46 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 7.64 CHEMBL

External reference:

IDSource
4021396 VUID
N0000148814 NUI
D01692 KEGG_DRUG
81403-68-1 SECONDARY_CAS_RN
17300 RXNORM
C0051150 UMLSCUI
CHEBI:51141 CHEBI
CHEMBL709 ChEMBL_ID
CHEMBL1723 ChEMBL_ID
DB00346 DRUGBANK_ID
C047638 MESH_SUPPLEMENTAL_RECORD_UI
2092 PUBCHEM_CID
7109 IUPHAR_LIGAND_ID
5357 INN_ID
90347YTW5F UNII
16517 MMSL
184661 MMSL
43057 MMSL
47077 MMSL
d04797 MMSL
4021396 VANDF
005431 NDDF
005432 NDDF
349912006 SNOMEDCT_US
395725004 SNOMEDCT_US
395954002 SNOMEDCT_US
90347YTW5F INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Alfuzosin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0440-5000 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 24 sections
Uroxatral HUMAN PRESCRIPTION DRUG LABEL 1 16590-279 TABLET, EXTENDED RELEASE 10 mg ORAL NDA 11 sections
Alfuzosin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 29300-155 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 17 sections
Alfuzosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 33261-994 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 25 sections
Alfuzosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 43353-746 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Alfuzosin hydrochloride Human Prescription Drug Label 1 43353-945 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 24 sections
Alfuzosin Hydrochloride Human Prescription Drug Label 1 47335-956 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Alfuzosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51655-087 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Alfuzosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51655-432 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Alfuzosin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51655-967 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 17 sections
Uroxatral HUMAN PRESCRIPTION DRUG LABEL 1 54868-5046 TABLET, EXTENDED RELEASE 10 mg ORAL NDA 28 sections
Alfuzosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54868-6329 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Alfuzosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 55648-738 TABLET 10 mg ORAL ANDA 25 sections
Alfuzosin Hydrochloride Human Prescription Drug Label 1 57237-114 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Uroxatral Human Prescription Drug Label 1 59212-200 TABLET, EXTENDED RELEASE 10 mg ORAL NDA 27 sections
Alfuzosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 60505-2850 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 25 sections
ALFUZOSIN HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 61919-349 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 18 sections
Alfuzosin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 63629-7907 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 17 sections
Alfuzosin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 63629-9155 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 17 sections
Alfuzosin Hydrochloride Human Prescription Drug Label 1 65862-249 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Alfuzosin Hydrochlorideextended release HUMAN PRESCRIPTION DRUG LABEL 1 69097-844 TABLET 10 mg ORAL ANDA 25 sections
Alfuzosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 70934-306 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Alfuzosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 71335-2146 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Alfuzosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 71335-2578 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Alfuzosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 72162-1449 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Alfuzosin hydrochloride Human Prescription Drug Label 1 76282-302 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 25 sections
Alfuzosin Hydrochloride Human Prescription Drug Label 1 84386-153 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections